BMS and OliPass partner to develop PNA-based therapeutics

Bristol-Myers Squibb Co. (NYSE:BMY) and OliPass Corp. (Suwon, South Korea) partnered to develop therapeutics against multiple targets using OliPass' peptide nucleic acid (PNA) technology platform.

OliPass will receive an undisclosed upfront payment and is eligible for development milestones and royalties. BMS will also provide research funding. ...